1.71
+0(+0.00%)
Currency In USD
| Previous Close | 1.71 |
| Open | 1.71 |
| Day High | 1.72 |
| Day Low | 1.66 |
| 52-Week High | 2.12 |
| 52-Week Low | 0.77 |
| Volume | 2.63M |
| Average Volume | 1.8M |
| Market Cap | 170.62M |
| PE | -4.75 |
| EPS | -0.36 |
| Moving Average 50 Days | 1.42 |
| Moving Average 200 Days | 1.24 |
| Change | 0 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of June 01, 2025 at a share price of $1.71. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $502.94 as of June 01, 2025 at a share price of $1.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewswire Inc.
May 15, 2025 12:45 PM GMT
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
GlobeNewswire Inc.
Apr 28, 2025 12:45 PM GMT
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or